1-9 of 9
Patricia Kropf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine Walsh, MD, Michael Savona, MD, Patricia Kropf, MD, Casey O'Connell, MD, Raoul Tibes, MD, Naval G. Daver, MD, Elias Jabbour, MD, Scott Lunin, MD, Todd L. Rosenblat, MD, Karen Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph R Mace, MD, Nikolai A. Podoltsev, MDPhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2014) 124 (21): 529.
https://doi.org/10.1182/blood.V124.21.529.529
Published: 2014
Journal Articles

Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study

Woonbok Chung, PhD, Pietro Taverna, PhD, John F Lyons, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Patricia Kropf, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 1442.
https://doi.org/10.1182/blood.V122.21.1442.1442
Published: 2013
Journal Articles

A Retrospective Analysis Of The Association Between Common Myeloablative Conditioning Regimens and Hepatotoxicity

Rushang D. Patel, MD, PhD, Thomas R. Klumpp, MD, Mary Ellen Martin, MD, Patricia Kropf, MD, Omotayo O. Fasan, MBBS, Kenneth F. Mangan, MD
Journal: Blood
Blood (2013) 122 (21): 5515.
https://doi.org/10.1182/blood.V122.21.5515.5515
Published: 2013
Journal Articles

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, H. Jean Khoury, MD, Patricia Kropf, MD, Mauricette Michallet, MD, PhD, Michele Baccarani, MD, Delphine Rea, MD, PhD, Charles Chuah, MD, Raghunadharao Digumarti, MD, Purvish M. Parikh, MD, PhD, Elizabeth Li, MS, Mihaela C. Munteanu, MS, Peter D. Brown, DPhil, Franck E. Nicolini, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2743.
https://doi.org/10.1182/blood.V122.21.2743.2743
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013
Journal Articles

Confirmation of A Strong Relationship Between Race and Probability of Transplant Among Patients Referred for Hematopoietic Cell Transplantation (HCT) for Hematological Maliganancies – A 17 Year Experience

Manish Sharma, MD, Thomas R Klumpp, MD, John A Ulicny, MS, Omotayo O. Fasan, MBBS, Patricia Kropf, MD, Mary Ellen Martin, MD, Kenneth F. Mangan, MD
Journal: Blood
Blood (2012) 120 (21): 4266.
https://doi.org/10.1182/blood.V120.21.4266.4266
Published: 2012
Journal Articles

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

Kenneth A. Foon, Dhaval Mehta, Suzanne Lentzsch, Patricia Kropf, Stanley Marks, Diana Lenzner, Louis Pietragallo, Mathew Sulecki, Ahmad Tarhini, Michael Boyiadzis
Journal: Blood
Blood (2012) 119 (13): 3184–3185.
https://doi.org/10.1182/blood-2012-01-408047
Published: 2012
Journal Articles

Evaluating Trends in Diagnostic and Prognostic Testing for Multiple Myeloma

C. J. Fidler, Ahmed Kamel Abou Hussein, MD, Neel Gandhi, Vinit Karur, MD, Manish Sharma, MD, Thomas R Klumpp, MD, Patricia Kropf, MD, Mary Ellen Martin, MD, Robert V. Emmons, MD, Kenneth F. Mangan, MD
Journal: Blood
Blood (2011) 118 (21): 2067.
https://doi.org/10.1182/blood.V118.21.2067.2067
Published: 2011
Journal Articles

LACK of ASSOCIATION BETWEEN Race and Probability of TRANSPLANT AMONG PATIENTS Referred for Hematopoietic CELL TRANSPLANTATION (HCT) for MULTIPLE Myeloma

Manish Sharma, MD, Michael Bromberg, MD, PhD, Thomas R. Klumpp, MD, Patricia Kropf, MD, Mary Ellen Martin, MD, Robert V. Emmons, MD, Kenneth F. Mangan, MD
Journal: Blood
Blood (2011) 118 (21): 3129.
https://doi.org/10.1182/blood.V118.21.3129.3129
Published: 2011